GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alembic Pharmaceuticals Ltd (BOM:533573) » Definitions » Retained Earnings

Alembic Pharmaceuticals (BOM:533573) Retained Earnings : ₹0 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Alembic Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Alembic Pharmaceuticals's retained earnings for the quarter that ended in Mar. 2024 was ₹0 Mil.

Alembic Pharmaceuticals's annual retained earnings increased from Mar. 2022 (₹25,544 Mil) to Mar. 2023 (₹35,684 Mil) but then declined from Mar. 2023 (₹35,684 Mil) to Mar. 2024 (₹0 Mil).


Alembic Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Alembic Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alembic Pharmaceuticals Retained Earnings Chart

Alembic Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,386.40 23,849.40 25,543.90 35,684.40 -

Alembic Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35,684.40 - - - -

Alembic Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Alembic Pharmaceuticals  (BOM:533573) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Alembic Pharmaceuticals (BOM:533573) Business Description

Traded in Other Exchanges
Address
Alembic Road, Vadodara, GJ, IND, 390 003
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Alembic Pharmaceuticals (BOM:533573) Headlines

No Headlines